1 hr ago
USFDA Warns Reliance Life Sciences Over Navi Mumbai Drug Lapses
The USFDA checked a drug-making facility in Navi Mumbai.
It said the facility had important problems with how it made and tested medicines.
Some laboratory records did not contain all the needed test information.
The regulator also said the company lacked proper procedures to prevent germs from contaminating sterile medicines.
Because of these concerns, the USFDA put the company’s drugs on an import alert.
This means the drugs offered for import into the United States face regulatory action.
The agency asked the company to find the causes of the problems.
It also asked Reliance Life Sciences to make lasting corrections so the issues do not happen again.
The USFDA issued a warning letter to Reliance Life Sciences Pvt Ltd.
The warning followed a February 19–27, 2026 inspection in Navi Mumbai.
Inspectors cited incomplete laboratory records for required testing and specifications.
The company allegedly lacked procedures to prevent microbiological contamination in sterile drugs.
All drugs offered by the company for US import were placed on import alert.
- Who
- The United States Food and Drug Administration and Reliance Life Sciences Pvt Ltd.
- What
- The USFDA issued a warning letter citing significant current good manufacturing practice violations and placed the company’s US-bound drugs on import alert.
- Where
- The inspection took place at the Dhirubhai Ambani Life Sciences Centre in Navi Mumbai, Maharashtra, India.
- When
- The facility was inspected from February 19 to 27, 2026; the article does not specify the warning letter’s date.
- Why
- The USFDA cited incomplete laboratory records and inadequate procedures for preventing microbiological contamination in sterile drug products.
Key facts
- Regulator
- United States Food and Drug Administration
- Company
- Reliance Life Sciences Pvt Ltd
- Facility
- Dhirubhai Ambani Life Sciences Centre
- Inspection dates
- February 19–27, 2026
- Main findings
- Incomplete laboratory data and inadequate procedures for preventing microbiological contamination
- Regulatory action
- All drugs and drug products offered for import into the United States were placed on import alert
- Required response
- Investigate root causes and implement corrective and preventive measures
Sources
Related news
USFDA Warns Dabur India Over Manufacturing Lapses at Silvassa Plant
Maharashtra FDA Cancels 10 Ayurvedic Licences Over GMP Violations
Aurobindo's Eugia Pharma Telangana Unit Gets USFDA Warning Letter
Bombay High Court Rebukes FDA, Cipla Licence Order Withdrawn
FDA cancels licence of ayurvedic firm Inducare Pharma
US FDA hails Andhra Pradesh pharma, urges stricter quality checks
NMMC Launches Navi Mumbai Drive to Protect Existing Trees
IWSA Opens Learning Garden Museum To Promote Urban Biodiversity
Mumbai Warehouse Found Relabeling Exported Maggi, Lay’s and Kurkure Packs
Bombay High Court Rejects Split Legal Challenges to Redevelopment
